GHRP-6 Research Guide: Growth Hormone Secretagogue Science (2025)

What Is GHRP-6?

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide growth hormone secretagogue. It was developed in the 1980s by Cyril Bowers and colleagues as part of systematic work to identify small peptides capable of stimulating GH release from the pituitary independent of GHRH.

Unlike GHRH analogues (Sermorelin, CJC-1295), which act on the GHRH-R to increase GH transcription, GHRP-6 acts on a distinct receptor — GHS-R1a — that was later identified as the endogenous receptor for ghrelin. This dual GHRH + GHRP axis discovery was pivotal in understanding GH secretion regulation.

Mechanism of Action

GHRP-6 exerts its primary effect through high-affinity binding to GHS-R1a. This receptor is expressed in highest density in the pituitary somatotrophs and in hypothalamic arcuate and ventromedial nuclei. Upon binding, it activates Gq/11 protein signalling, triggering IP₃-mediated intracellular Ca²⁺ release and PKC activation, which drives GH granule exocytosis.

Simultaneously, GHRP-6 stimulates hypothalamic neurons to release GHRH and suppresses somatostatin release. This two-site action — direct pituitary stimulation plus hypothalamic modulation — produces larger GH pulses than GHRH alone. The combination of a GHRP with a GHRH analogue (e.g., GHRP-6 + CJC-1295) yields supra-additive GH release in animal models.

GH & IGF-1 Axis Effects

In rodent studies, subcutaneous GHRP-6 at 100–300 µg/kg produces acute GH pulses 3–8× above baseline within 15–30 minutes, returning to baseline within 2–3 hours. Chronic administration (14–21 days) elevates mean 24-hour GH and serum IGF-1 levels significantly above controls.

In early human clinical research (pre-1990s), IV GHRP-6 at 1 µg/kg elicited GH responses comparable to GHRH administration, with peak GH levels of 15–30 ng/mL. Co-administration with GHRH produced synergistic responses often exceeding 60–80 ng/mL — establishing the physiological significance of dual GH-axis stimulation.

The pulsatile nature of GHRP-6-induced GH release is physiologically important — it preserves feedback loops and avoids the receptor desensitisation associated with continuous GH receptor activation (as seen with exogenous GH injection).

Hunger & Ghrelin Effects

Because GHS-R1a is the endogenous receptor for ghrelin — the "hunger hormone" — GHRP-6 reliably stimulates appetite through the same orexigenic pathways. GHS-R1a activation in the hypothalamic arcuate nucleus increases NPY (neuropeptide Y) and AgRP (agouti-related peptide) release, which powerfully suppresses satiety signals and increases food intake.

In animal models, GHRP-6 significantly increases food intake 30–60 minutes post-injection. This hunger effect is dose-dependent and attenuated (but not abolished) by GHRH receptor antagonists, confirming it is primarily GHS-R1a-mediated rather than secondary to GH elevation.

This orexigenic property distinguishes GHRP-6 from Ipamorelin, which produces minimal hunger stimulation despite similar GH release — a critical consideration when selecting GHRPs for research models involving feeding behaviour.

Cardiovascular & Cytoprotective Research

A body of preclinical literature, largely from the 2000s–2010s, documents GHS-R1a-mediated cardioprotection by GHRP-6 independent of its GH-releasing effects. This is consistent with ghrelin's known cardioprotective role and the expression of GHS-R1a in cardiomyocytes.

Key Preclinical Findings

• Ischaemia-reperfusion (I/R) injury: GHRP-6 pre-treatment reduced infarct size by 30–45% in rodent cardiac I/R models, associated with activation of PI3K/Akt and ERK1/2 survival pathways and suppression of apoptosis.
• Anti-fibrotic effects: Chronic GHRP-6 reduced cardiac fibrosis markers (TGF-β1, collagen deposition) in pressure-overload heart failure models.
• Hepatoprotection: GHRP-6 attenuated NASH-related liver fibrosis and reduced hepatocyte apoptosis in high-fat diet rodent models via GHS-R1a → Akt signalling.
• Wound healing: Topical and systemic GHRP-6 accelerated wound closure and granulation tissue formation in rodent excision models.

These effects are considered to be partially GH-independent, mediated by direct GHS-R1a signalling in peripheral tissues (cardiomyocytes, hepatocytes, fibroblasts).

GHRP Family Comparison

Multiple GHRPs have been developed and studied. They share the GHS-R1a target but differ in selectivity, potency, and side-effect profile:

Ipamorelin's superior selectivity profile — high GH release without significant cortisol/prolactin elevation or hunger — makes it the preferred GHRP in most modern research designs. GHRP-6 remains valuable where ghrelin-pathway biology or appetite effects are the research focus.

Research Protocols

Safety Profile in Research Models

GHRP-6 demonstrates a well-characterised safety profile in preclinical models across decades of research:

• Acute toxicity: No significant toxicity at standard research doses in rodents. High doses (mg/kg range) may elevate cortisol; this is a known effect mediated via GHS-R1a in the hypothalamic-pituitary-adrenal axis.
• Receptor desensitisation: Repeated high-frequency dosing leads to GHS-R1a desensitisation and attenuated GH response. Pulsatile protocols (2–3× daily) preserve receptor sensitivity better than continuous infusion.
• Hypoglycaemia risk: GH secretion is transiently insulinotropic; combined with strong IGF-1 elevation in chronic models, transient glucose changes may occur. Monitor blood glucose in metabolic studies.
• Prolactin elevation: Moderate prolactin rise observed in human pharmacology studies; return to baseline within 2–3 hours of dosing.

Frequently Asked Questions